USANA Health Sciences (NYSE:USNA) Insider Sells $97,288.90 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Brent Neidig sold 5,002 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total value of $97,288.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

USANA Health Sciences Trading Up 4.1%

NYSE:USNA traded up $0.76 during mid-day trading on Thursday, hitting $19.16. 39,164 shares of the company’s stock traded hands, compared to its average volume of 123,440. The firm has a 50 day moving average of $18.72 and a two-hundred day moving average of $19.42. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32. The firm has a market capitalization of $353.62 million, a price-to-earnings ratio of 40.81, a price-to-earnings-growth ratio of 0.75 and a beta of 0.76.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. As a group, equities research analysts expect that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. Finally, Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

Institutional Trading of USANA Health Sciences

Several large investors have recently made changes to their positions in the company. National Bank of Canada FI lifted its position in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after buying an additional 1,201 shares in the last quarter. State of Wyoming bought a new stake in shares of USANA Health Sciences in the 1st quarter worth approximately $57,000. Tower Research Capital LLC TRC raised its holdings in USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after acquiring an additional 1,901 shares during the period. Parallel Advisors LLC lifted its holdings in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after buying an additional 3,589 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after acquiring an additional 1,327 shares during the period. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.